Gene therapy of gastrointestinal cancer using adenoviral vector

利用腺病毒载体进行胃肠道癌症的基因治疗

基本信息

  • 批准号:
    07671380
  • 负责人:
  • 金额:
    $ 1.54万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1995
  • 资助国家:
    日本
  • 起止时间:
    1995 至 1996
  • 项目状态:
    已结题

项目摘要

The possibility of using adenoviruses for gene therapy of gastrointestinal cancer was investigated. First, a lacZ gene with an inserted adenovirus (AxlacZ) was used as a reporter gene for in vitro and in vivo infection experiments. Cultured cell strains from esophageal, stomach, and large intestinal cancers were placed in contact with AxlacZ in vitro, and the adenovirus infectivity was examined using X-gal stain. A considerable difference in infectivity was seen between the cell strains, varying from about 20% to nearly 100%. Next, the cell line was implanted subcutaneously in nude mice, AxlacZ was injected directly into the tumor, and several days later the tumor was excised. It was then stained with X-gal, and the adenovirus infection was confirmed. In addition, cellular immunity from the adenovirus was investigated using BALB/c mice and large intestinal cancer cell line colon 26 from them. AxlacZ was first administered into the mouse abdominal cavity, and afterward colon 26 infected … More with AxlacZ was implanted into the mice. Tumor growth was suppressed compared to when no AxlacZ pre-treatment was given, suggesting establishment of cellular immunity.Next, recombinant adenovirus (Axp53) expressing wild-type p53 was prepared, and used to investigated the antitumoral effect in the esophageal cancer cell line in vitro and in vivo. The cell line was infected with Axp53 in vitro and cell survival was examined in an MTT assay. A variation of about 20% to 90% was seen, depending on the cell line. In the in vivo investigation, the cell line was implanted subcutancously in nude mice, and AxlacZ or Axp53 was injected directly. Suppression of cell proliferation was seen with AxlacZ,but Axp53 proved to be even more effective. In the region of the Axp53 injection p53 protein expression was confirmed by immunostaining. The combination of Axp53 with an anticancer agent was also investigated both in vitro and in vivo, but only an additive effect was obtained.In light of the foregoing, p53 recombinant adenovirus is seen to be an effective gene therapy for gastrointestinal cancer. Less
探讨腺病毒用于胃肠道肿瘤基因治疗的可能性。首先,将具有插入的腺病毒(AxlacZ)的lacZ基因用作报告基因用于体外和体内感染实验。将来自食管癌、胃癌和大肠癌的培养细胞株置于体外与AxlacZ接触,并使用X-gal染色检查腺病毒感染性。在细胞株之间观察到感染性的相当大的差异,从约20%变化到接近100%。接下来,将细胞系皮下植入裸鼠,将AxlacZ直接注射到肿瘤中,几天后切除肿瘤。然后用X-gal染色,确认腺病毒感染。此外,使用BALB/c小鼠和来自它们的大肠癌细胞系colon 26研究来自腺病毒的细胞免疫。首先将AxlacZ注入小鼠腹腔,随后将结肠26感染 ...更多信息 植入小鼠体内。与未给予AxlacZ预处理时相比,肿瘤生长受到抑制,表明细胞免疫的建立。接下来,制备表达野生型p53的重组腺病毒(Axp 53),并用于在体外和体内研究食管癌细胞系中的抗肿瘤效果。在体外用Axp 53感染细胞系,并在MTT测定中检查细胞存活。根据细胞系,观察到约20%至90%的变化。在体内研究中,将细胞系皮下植入裸鼠中,并直接注射AxlacZ或Axp 53。用AxlacZ观察到细胞增殖的抑制,但Axp 53被证明甚至更有效。在Axp 53注射区域,通过免疫染色证实p53蛋白表达。Axp 53与抗癌剂的组合也在体外和体内进行了研究,但仅获得了累加效应。少

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hroyuki, Sekiguchi: "Efficient adenovirus-mediated gene transter into human cancer cell lines derived from digestive tract" International Journal of Oncology. 8. 283-287 (1996)
Hroyuki,Sekiguchi:“有效的腺病毒介导的基因转移到源自消化道的人类癌细胞系”国际肿瘤学杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hiroyuki Sekiguchi, Ken-ichi Isobe, Seiji Akiyama, Hong Yi, Hiroki Takeshita, Tadashi Watanabe, Yasushi Kasai, Katsuki Ito, Yumi Kanegae, Izumu Saito, Izumi Nakashima and Hiroshi Takagi: "Efficient adenovirus-mediated gene transfer into human cancer cell
Hiroyuki Sekiguchi、Ken-ichi Isobe、Seiji Akiyama、Hong Yi、Hiroki Takeshita、Tadashi Watanabe、Yasushi Kasai、Katsuki Ito、Yumi Kanegae、Izumu Saito、Izumi Nakashima 和 Hiroshi Takagi:“高效腺病毒介导的基因转移到人类癌细胞中
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hiroyuki Sekiguchi: "Efficient adenovirus-mediated gene transfer into human cancer cell lines derived from digestive tract" International Journal of Oncology. 8. 283-287 (1996)
Hiroyuki Sekiguchi:“有效的腺病毒介导的基因转移到源自消化道的人类癌细胞系”国际肿瘤学杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AKIYAMA Seiji其他文献

AKIYAMA Seiji的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AKIYAMA Seiji', 18)}}的其他基金

Sensitivity test of anticancer agents using 31P NMP Spectroscopy
使用 31P NMP 光谱法进行抗癌药物的敏感性测试
  • 批准号:
    02670539
  • 财政年份:
    1990
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Fundamental Research for Intervention of Poor Prognostic Factors and Strengthening of Surgical Care System for Gastrointestinal Cancer in Community Medicine
社区医学中胃肠癌不良预后因素干预和加强外科护理体系的基础研究
  • 批准号:
    23K16289
  • 财政年份:
    2023
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigation of the oncogenic mechanism of novel oncogene SETDB1 in gastrointestinal cancer
新癌基因SETDB1在胃肠道癌中的致癌机制研究
  • 批准号:
    23K08116
  • 财政年份:
    2023
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Functional analysis of BAP1 in the control of gastrointestinal cancer progression and metastasis.
BAP1在控制胃肠癌进展和转移中的功能分析。
  • 批准号:
    23K08126
  • 财政年份:
    2023
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Functional analysis of inflammation-inducing bacteria derived form oral microflora and immunoreactive T cells in gastrointestinal cancer
胃肠癌中口腔微生物群和免疫反应性 T 细胞衍生的炎症诱导细菌的功能分析
  • 批准号:
    23K08201
  • 财政年份:
    2023
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multi-site Gastrointestinal Cancer Detection by Stool DNA Methylation
通过粪便 DNA 甲基化进行多部位胃肠癌检测
  • 批准号:
    10443018
  • 财政年份:
    2023
  • 资助金额:
    $ 1.54万
  • 项目类别:
Improving Diagnosis in Gastrointestinal Cancer: Integrating Prediction Models into Routine Clinical Care
改善胃肠癌的诊断:将预测模型纳入常规临床护理
  • 批准号:
    10641060
  • 财政年份:
    2023
  • 资助金额:
    $ 1.54万
  • 项目类别:
Study on fibrotic niche generation for promotion of gastrointestinal cancer metastasis
纤维化微环境生成促进胃肠癌转移的研究
  • 批准号:
    22KF0154
  • 财政年份:
    2023
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of AI-based hospital stay management support system - Perioperative DPC data exploration for gastrointestinal cancer
基于AI的住院管理支持系统开发——消化道肿瘤围手术期DPC数据探索
  • 批准号:
    22K10407
  • 财政年份:
    2022
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patients
系统液体活检监测胃肠道癌症患者的残留病灶和治疗效果
  • 批准号:
    10697368
  • 财政年份:
    2022
  • 资助金额:
    $ 1.54万
  • 项目类别:
Analysis of the mechanism of acquisition of anticancer drug resistance using gastrointestinal cancer organoids
胃肠道肿瘤类器官获得抗癌耐药性的机制分析
  • 批准号:
    22K07013
  • 财政年份:
    2022
  • 资助金额:
    $ 1.54万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了